Literature DB >> 25245981

Clinical cancer research: the past, present and the future.

Vincent T DeVita1, Alexander M M Eggermont2, Samuel Hellman3, David J Kerr4.   

Abstract

In the past decade, we have witnessed unprecedented changes and some remarkable advances that have enabled true personalized medicine. Nevertheless, many challenges in clinical cancer research remain and need to be overcome if we are to witness similar progress in the next decade. Such hurdles include, but are not limited to, clinical development and testing of multiple agents in combination, design of clinical trials to best accommodate the ever increasing knowledge of heterogeneity of the disease, regulatory challenges relating to drug development and trial design, and funding for basic research. With this in mind, we asked four leading cancer researchers from around the world, and who have been associated with the journal since its launch in November 2004 what, in their opinion, we have learnt over the past 10 years and how we should progress in the next 10 years.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25245981     DOI: 10.1038/nrclinonc.2014.153

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  34 in total

1.  Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group.

Authors:  David M Dilts; Alan Sandler; Steven Cheng; Joshua Crites; Lori Ferranti; Amy Wu; Robert Gray; Jean MacDonald; Donna Marinucci; Robert Comis
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

2.  Melanoma: smart therapeutic strategies in immuno-oncology.

Authors:  Alexander M M Eggermont; Caroline Robert
Journal:  Nat Rev Clin Oncol       Date:  2014-03-04       Impact factor: 66.675

Review 3.  Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.

Authors:  Ester Simeone; Paolo A Ascierto
Journal:  J Immunotoxicol       Date:  2012-04-23       Impact factor: 3.000

4.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

5.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

6.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

7.  Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Authors:  Monica Garcia-Barros; Francois Paris; Carlos Cordon-Cardo; David Lyden; Shahin Rafii; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

8.  Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

Authors:  Enric Domingo; David N Church; Oliver Sieber; Rajarajan Ramamoorthy; Yoko Yanagisawa; Elaine Johnstone; Brian Davidson; David J Kerr; Ian P M Tomlinson; Rachel Midgley
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 10.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

Authors:  Nicholas B La Thangue; David J Kerr
Journal:  Nat Rev Clin Oncol       Date:  2011-08-23       Impact factor: 66.675

View more
  11 in total

1.  Reflections on nutritional cancer epidemiology.

Authors:  Paolo Boffetta
Journal:  Am J Clin Nutr       Date:  2015-12-16       Impact factor: 7.045

Review 2.  Fasting and cancer: molecular mechanisms and clinical application.

Authors:  Alessio Nencioni; Irene Caffa; Salvatore Cortellino; Valter D Longo
Journal:  Nat Rev Cancer       Date:  2018-11       Impact factor: 60.716

3.  ID-Checker Technology for the Highly Selective Macroscale Delivery of Anticancer Agents to the Cancer Cells.

Authors:  Keum-Soo Song; Satish Balasaheb Nimse; Junghoon Kim; Shrikant Dashrath Warkad; Taisun Kim
Journal:  J Med Chem       Date:  2022-10-04       Impact factor: 8.039

4.  Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy.

Authors:  Gonzalo Recondo; Linda Mahjoubi; Aline Maillard; Yohann Loriot; Ludovic Bigot; Francesco Facchinetti; Rastislav Bahleda; Anas Gazzah; Antoine Hollebecque; Laura Mezquita; David Planchard; Charles Naltet; Pernelle Lavaud; Ludovic Lacroix; Catherine Richon; Aurelie Abou Lovergne; Thierry De Baere; Lambros Tselikas; Olivier Deas; Claudio Nicotra; Maud Ngo-Camus; Rosa L Frias; Eric Solary; Eric Angevin; Alexander Eggermont; Ken A Olaussen; Gilles Vassal; Stefan Michiels; Fabrice Andre; Jean-Yves Scoazec; Christophe Massard; Jean-Charles Soria; Benjamin Besse; Luc Friboulet
Journal:  NPJ Precis Oncol       Date:  2020-09-08

5.  The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis.

Authors:  Luisana Astudillo; Thiago G Da Silva; Zhiqiang Wang; Xiaoqing Han; Ke Jin; Jeffrey VanWye; Xiaoxia Zhu; Kelly Weaver; Taiji Oashi; Pedro E M Lopes; Darren Orton; Leif R Neitzel; Ethan Lee; Ralf Landgraf; David J Robbins; Alexander D MacKerell; Anthony J Capobianco
Journal:  Cancer Res       Date:  2016-04-13       Impact factor: 12.701

6.  Commentary on Hey and Kimmelman.

Authors:  J Jack Lee
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

7.  Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology.

Authors:  Stefanie Broes; Denis Lacombe; Michiel Verlinden; Isabelle Huys
Journal:  Front Med (Lausanne)       Date:  2018-01-29

8.  Engineering Circulating Tumor Cells as Novel Cancer Theranostics.

Authors:  Katie M Parkins; Veronica P Dubois; John J Kelly; Yuanxin Chen; Natasha N Knier; Paula J Foster; John A Ronald
Journal:  Theranostics       Date:  2020-06-29       Impact factor: 11.556

Review 9.  Unsolved challenges of clinical whole-exome sequencing: a systematic literature review of end-users' views.

Authors:  Gabrielle Bertier; Martin Hétu; Yann Joly
Journal:  BMC Med Genomics       Date:  2016-08-11       Impact factor: 3.063

Review 10.  Whole-Transcriptome Sequencing: a Powerful Tool for Vascular Tissue Engineering and Endothelial Mechanobiology.

Authors:  Anton G Kutikhin; Maxim Yu Sinitsky; Arseniy E Yuzhalin; Elena A Velikanova
Journal:  High Throughput       Date:  2018-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.